Drug Testing Guides

SAMHSA-5 standard: THC, cocaine, opiates, amphetamines, PCP. The most commonly ordered workplace panel.

Extends the 5-panel with benzodiazepines, barbiturates, methadone, propoxyphene, and methaqualone.

Adds oxycodone and buprenorphine to the 10-panel — widely used in clinical and addiction medicine settings.

Ethyl glucuronide (EtG) detects alcohol consumption for up to 80 hours after drinking — used in probation, rehab, and court monitoring.

Fentanyl, buprenorphine, tramadol, methadone, and synthetic opioid confirmation — critical for pain clinic and addiction monitoring.

Diazepam, lorazepam, alprazolam, clonazepam — standard and confirmatory benzodiazepine detection with individual identification.

MDMA (ecstasy), methamphetamine, Adderall (mixed amphetamine salts) — with LC-MS/MS confirmation to distinguish prescribed from illicit use.

THC metabolite (THC-COOH) detection in urine. Includes cut-off thresholds, detection windows by use frequency, and how to interpret a positive in a medical cannabis patient.

Point-of-care saliva drug testing — detects recent use within hours. Covers THC, cocaine, amphetamines, benzodiazepines, opiates. Used in roadside and workplace testing.

90-day detection window for chronic drug use patterns. Cannot detect single-use episodes. Covers most major drug classes in a segmented timeline.

Kratom is not detected by standard drug panels. Specific immunoassay and LC-MS/MS confirmation are required — growing relevance in pain and opioid recovery settings.

DOT-regulated and non-DOT workplace programmes — collection procedures, MRO review, split specimen protocols, and employee rights explained.